We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bristol Myers Squibb Snaps up Mirati and Its KRAS-Targeting Cancer Pipeline
Bristol Myers Squibb Snaps up Mirati and Its KRAS-Targeting Cancer Pipeline
In a move to strengthen its KRAS-targeting oncology portfolio, Bristol Myers Squibb is buying Mirati, the company that developed and launched Krazati (adagrasib), a best-in-class molecule that, when combined with a PD-1 inhibitor, targets non-small cell lung cancers harboring the common mutation.